Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study

Click chemistry was used to synthesize a new series of thioquinazolinone molecules equipped with propargyl moiety,1,2,3-triazolyl and isoxazolyl rings. Our design was based on merging pharmacophores previously reported to exhibit COX-2 inhibitory activities to a thioquinazolinone-privileged scaffold...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2018-01, Vol.144, p.635-650
Hauptverfasser: Moussa, Ghandoura, Alaaeddine, Rana, Alaeddine, Lynn M., Nassra, Rasha, Belal, Ahmed S.F., Ismail, Azza, El-Yazbi, Ahmed F., Abdel-Ghany, Yasser S., Hazzaa, Aly
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 650
container_issue
container_start_page 635
container_title European journal of medicinal chemistry
container_volume 144
creator Moussa, Ghandoura
Alaaeddine, Rana
Alaeddine, Lynn M.
Nassra, Rasha
Belal, Ahmed S.F.
Ismail, Azza
El-Yazbi, Ahmed F.
Abdel-Ghany, Yasser S.
Hazzaa, Aly
description Click chemistry was used to synthesize a new series of thioquinazolinone molecules equipped with propargyl moiety,1,2,3-triazolyl and isoxazolyl rings. Our design was based on merging pharmacophores previously reported to exhibit COX-2 inhibitory activities to a thioquinazolinone-privileged scaffold. The synthesized compounds were subjected to in vitro cyclooxygenase COX-1/COX-2 and 15-LOX inhibition assays. Compounds 2c, 3b, 3h, 3j, and 3k showed COX-2 inhibition with IC50 (μM) 0.18, 0.19, 0.11, 0.16 and 0.17 respectively. These values were compared to celecoxib (IC50 0.05 μM), diclofenac (IC50 0.8 μM) and indomethacin (IC50 0.49 μM) reference drugs. They also showed 15-LOX inhibition with IC50 (μM) 6.21, 4.33, 7.62, 5.21 and 3.98 respectively. These values were compared with Zileuton (IC50 2.41 μM) and Meclofenamate sodium (IC50 5.64 μM) as positive controls. These compounds were further challenged by PMA-induced THP-1 differentiation assay where compounds 2c and 3j inhibited monocyte to macrophage differentiation efficiently with IC50 values of 4.78 μM and 5.63 μM, respectively, compared to that of diclofenac sodium (4.86 μM). On the other hand, 3h demonstrated a significantly increased potency compared to diclofenac in this assay (IC50 = 0.13 μM). The same compounds exhibited significant in vivo anti-inflammatory effect as indicated by the formalin-induced rat-paw edema test. Docking experiments of compounds 2c, 3b, 3h, 3j, and 3k into COX-2 binding pocket have been conducted, where strong binding interactions have been identified and effective overall docking scores have been recorded. Their drug-likeness has been assessed using Molinspiration, Molsoft and Pre-ADMET software products. A new series of propargyl and 1,2,3-Triazolyl thioquinazolinone showed dual COX-2 and LOX inhibitory activity. [Display omitted] •A new series of propargyl, triazolyl and isoxazolyl derivatives of thioquinazolinone were synthesized via click chemistry.•Compounds 2c, 3b, 3h, 3j, and 3k showed dual selective COX-2 and 15-LOX inhibition.•Compounds 2c, 3b, 3h and 3j inhibited in vitro monocyte to macrophage differentiation.•They showed in vivo anti-inflammatory activity and acceptable GIT safety on experimental animals.•Their docking experiments and drug-likeness assessment were satisfactory.
doi_str_mv 10.1016/j.ejmech.2017.12.065
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1983255799</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523417310966</els_id><sourcerecordid>1983255799</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-a0f687933709ac1b8e45aa7c78e33b54e332ee9dbe06cc6fa3e08f34adde5a7e3</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EotvCP0DIRw5N8EcSJxyQqlI-pAoucLYce7I7W8cusbPScuOf42oLR6TRzBze9x3NQ8grzmrOePd2X8N-BrurBeOq5qJmXfuEbLjq-kqKtnlKNkwIWbVCNmfkPKU9Y6ztGHtOzsQg-qHv1Yb8_hoP4Kn1aO_oHB1OaEYPNO8w_lwxmF_RY4gBEjWlQsYKw-TNPJsclyM1Wwg5vaMfIOE2XNJ0DHlX9nRJR4w-btEaT-Fg_GoyxlAiHHXR3mHY0pRXd3xBnk3GJ3j5OC_Ij483368_V7ffPn25vrqtrOxErgybul4NUio2GMvHHprWGGVVD1KObVO6ABjcCKyztpuMBNZPsjHOQWsUyAvy5pR7v5TPIGU9Y7LgvQkQ16T50BdsrRqGIm1OUrvElBaY9P2Cs1mOmjP9AF_v9Qm-foCvudAFfrG9frywjjO4f6a_tIvg_UkA5c8DwqKTRQgWHC5gs3YR_3_hD2UVm3M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1983255799</pqid></control><display><type>article</type><title>Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Moussa, Ghandoura ; Alaaeddine, Rana ; Alaeddine, Lynn M. ; Nassra, Rasha ; Belal, Ahmed S.F. ; Ismail, Azza ; El-Yazbi, Ahmed F. ; Abdel-Ghany, Yasser S. ; Hazzaa, Aly</creator><creatorcontrib>Moussa, Ghandoura ; Alaaeddine, Rana ; Alaeddine, Lynn M. ; Nassra, Rasha ; Belal, Ahmed S.F. ; Ismail, Azza ; El-Yazbi, Ahmed F. ; Abdel-Ghany, Yasser S. ; Hazzaa, Aly</creatorcontrib><description>Click chemistry was used to synthesize a new series of thioquinazolinone molecules equipped with propargyl moiety,1,2,3-triazolyl and isoxazolyl rings. Our design was based on merging pharmacophores previously reported to exhibit COX-2 inhibitory activities to a thioquinazolinone-privileged scaffold. The synthesized compounds were subjected to in vitro cyclooxygenase COX-1/COX-2 and 15-LOX inhibition assays. Compounds 2c, 3b, 3h, 3j, and 3k showed COX-2 inhibition with IC50 (μM) 0.18, 0.19, 0.11, 0.16 and 0.17 respectively. These values were compared to celecoxib (IC50 0.05 μM), diclofenac (IC50 0.8 μM) and indomethacin (IC50 0.49 μM) reference drugs. They also showed 15-LOX inhibition with IC50 (μM) 6.21, 4.33, 7.62, 5.21 and 3.98 respectively. These values were compared with Zileuton (IC50 2.41 μM) and Meclofenamate sodium (IC50 5.64 μM) as positive controls. These compounds were further challenged by PMA-induced THP-1 differentiation assay where compounds 2c and 3j inhibited monocyte to macrophage differentiation efficiently with IC50 values of 4.78 μM and 5.63 μM, respectively, compared to that of diclofenac sodium (4.86 μM). On the other hand, 3h demonstrated a significantly increased potency compared to diclofenac in this assay (IC50 = 0.13 μM). The same compounds exhibited significant in vivo anti-inflammatory effect as indicated by the formalin-induced rat-paw edema test. Docking experiments of compounds 2c, 3b, 3h, 3j, and 3k into COX-2 binding pocket have been conducted, where strong binding interactions have been identified and effective overall docking scores have been recorded. Their drug-likeness has been assessed using Molinspiration, Molsoft and Pre-ADMET software products. A new series of propargyl and 1,2,3-Triazolyl thioquinazolinone showed dual COX-2 and LOX inhibitory activity. [Display omitted] •A new series of propargyl, triazolyl and isoxazolyl derivatives of thioquinazolinone were synthesized via click chemistry.•Compounds 2c, 3b, 3h, 3j, and 3k showed dual selective COX-2 and 15-LOX inhibition.•Compounds 2c, 3b, 3h and 3j inhibited in vitro monocyte to macrophage differentiation.•They showed in vivo anti-inflammatory activity and acceptable GIT safety on experimental animals.•Their docking experiments and drug-likeness assessment were satisfactory.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2017.12.065</identifier><identifier>PMID: 29289887</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Animals ; Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis ; Anti-Inflammatory Agents, Non-Steroidal - chemistry ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Arachidonate 15-Lipoxygenase - metabolism ; Cell Differentiation - drug effects ; Click Chemistry ; Click reaction ; Cyclooxygenase 1 - metabolism ; Cyclooxygenase 1/cyclooxygenase 2 ; Cyclooxygenase 2 - metabolism ; Cyclooxygenase Inhibitors - chemical synthesis ; Cyclooxygenase Inhibitors - chemistry ; Cyclooxygenase Inhibitors - pharmacology ; Docking ; Dose-Response Relationship, Drug ; Drug Design ; Drug-likeness ; Female ; Humans ; Lipooxygenase ; Lipoxygenase Inhibitors - chemical synthesis ; Lipoxygenase Inhibitors - chemistry ; Lipoxygenase Inhibitors - pharmacology ; Macrophages - drug effects ; Molecular Docking Simulation ; Molecular Structure ; Monocyte/macrophage ; Quinazolinones - chemical synthesis ; Quinazolinones - chemistry ; Quinazolinones - pharmacology ; Rats ; Rats, Wistar ; Structure-Activity Relationship ; Sulfhydryl Compounds - chemical synthesis ; Sulfhydryl Compounds - chemistry ; Sulfhydryl Compounds - pharmacology ; Thioquinazolinone ; Tumor Cells, Cultured</subject><ispartof>European journal of medicinal chemistry, 2018-01, Vol.144, p.635-650</ispartof><rights>2017 Elsevier Masson SAS</rights><rights>Copyright © 2017 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-a0f687933709ac1b8e45aa7c78e33b54e332ee9dbe06cc6fa3e08f34adde5a7e3</citedby><cites>FETCH-LOGICAL-c362t-a0f687933709ac1b8e45aa7c78e33b54e332ee9dbe06cc6fa3e08f34adde5a7e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0223523417310966$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29289887$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Moussa, Ghandoura</creatorcontrib><creatorcontrib>Alaaeddine, Rana</creatorcontrib><creatorcontrib>Alaeddine, Lynn M.</creatorcontrib><creatorcontrib>Nassra, Rasha</creatorcontrib><creatorcontrib>Belal, Ahmed S.F.</creatorcontrib><creatorcontrib>Ismail, Azza</creatorcontrib><creatorcontrib>El-Yazbi, Ahmed F.</creatorcontrib><creatorcontrib>Abdel-Ghany, Yasser S.</creatorcontrib><creatorcontrib>Hazzaa, Aly</creatorcontrib><title>Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Click chemistry was used to synthesize a new series of thioquinazolinone molecules equipped with propargyl moiety,1,2,3-triazolyl and isoxazolyl rings. Our design was based on merging pharmacophores previously reported to exhibit COX-2 inhibitory activities to a thioquinazolinone-privileged scaffold. The synthesized compounds were subjected to in vitro cyclooxygenase COX-1/COX-2 and 15-LOX inhibition assays. Compounds 2c, 3b, 3h, 3j, and 3k showed COX-2 inhibition with IC50 (μM) 0.18, 0.19, 0.11, 0.16 and 0.17 respectively. These values were compared to celecoxib (IC50 0.05 μM), diclofenac (IC50 0.8 μM) and indomethacin (IC50 0.49 μM) reference drugs. They also showed 15-LOX inhibition with IC50 (μM) 6.21, 4.33, 7.62, 5.21 and 3.98 respectively. These values were compared with Zileuton (IC50 2.41 μM) and Meclofenamate sodium (IC50 5.64 μM) as positive controls. These compounds were further challenged by PMA-induced THP-1 differentiation assay where compounds 2c and 3j inhibited monocyte to macrophage differentiation efficiently with IC50 values of 4.78 μM and 5.63 μM, respectively, compared to that of diclofenac sodium (4.86 μM). On the other hand, 3h demonstrated a significantly increased potency compared to diclofenac in this assay (IC50 = 0.13 μM). The same compounds exhibited significant in vivo anti-inflammatory effect as indicated by the formalin-induced rat-paw edema test. Docking experiments of compounds 2c, 3b, 3h, 3j, and 3k into COX-2 binding pocket have been conducted, where strong binding interactions have been identified and effective overall docking scores have been recorded. Their drug-likeness has been assessed using Molinspiration, Molsoft and Pre-ADMET software products. A new series of propargyl and 1,2,3-Triazolyl thioquinazolinone showed dual COX-2 and LOX inhibitory activity. [Display omitted] •A new series of propargyl, triazolyl and isoxazolyl derivatives of thioquinazolinone were synthesized via click chemistry.•Compounds 2c, 3b, 3h, 3j, and 3k showed dual selective COX-2 and 15-LOX inhibition.•Compounds 2c, 3b, 3h and 3j inhibited in vitro monocyte to macrophage differentiation.•They showed in vivo anti-inflammatory activity and acceptable GIT safety on experimental animals.•Their docking experiments and drug-likeness assessment were satisfactory.</description><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - chemistry</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Arachidonate 15-Lipoxygenase - metabolism</subject><subject>Cell Differentiation - drug effects</subject><subject>Click Chemistry</subject><subject>Click reaction</subject><subject>Cyclooxygenase 1 - metabolism</subject><subject>Cyclooxygenase 1/cyclooxygenase 2</subject><subject>Cyclooxygenase 2 - metabolism</subject><subject>Cyclooxygenase Inhibitors - chemical synthesis</subject><subject>Cyclooxygenase Inhibitors - chemistry</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>Docking</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Design</subject><subject>Drug-likeness</subject><subject>Female</subject><subject>Humans</subject><subject>Lipooxygenase</subject><subject>Lipoxygenase Inhibitors - chemical synthesis</subject><subject>Lipoxygenase Inhibitors - chemistry</subject><subject>Lipoxygenase Inhibitors - pharmacology</subject><subject>Macrophages - drug effects</subject><subject>Molecular Docking Simulation</subject><subject>Molecular Structure</subject><subject>Monocyte/macrophage</subject><subject>Quinazolinones - chemical synthesis</subject><subject>Quinazolinones - chemistry</subject><subject>Quinazolinones - pharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Structure-Activity Relationship</subject><subject>Sulfhydryl Compounds - chemical synthesis</subject><subject>Sulfhydryl Compounds - chemistry</subject><subject>Sulfhydryl Compounds - pharmacology</subject><subject>Thioquinazolinone</subject><subject>Tumor Cells, Cultured</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhi0EotvCP0DIRw5N8EcSJxyQqlI-pAoucLYce7I7W8cusbPScuOf42oLR6TRzBze9x3NQ8grzmrOePd2X8N-BrurBeOq5qJmXfuEbLjq-kqKtnlKNkwIWbVCNmfkPKU9Y6ztGHtOzsQg-qHv1Yb8_hoP4Kn1aO_oHB1OaEYPNO8w_lwxmF_RY4gBEjWlQsYKw-TNPJsclyM1Wwg5vaMfIOE2XNJ0DHlX9nRJR4w-btEaT-Fg_GoyxlAiHHXR3mHY0pRXd3xBnk3GJ3j5OC_Ij483368_V7ffPn25vrqtrOxErgybul4NUio2GMvHHprWGGVVD1KObVO6ABjcCKyztpuMBNZPsjHOQWsUyAvy5pR7v5TPIGU9Y7LgvQkQ16T50BdsrRqGIm1OUrvElBaY9P2Cs1mOmjP9AF_v9Qm-foCvudAFfrG9frywjjO4f6a_tIvg_UkA5c8DwqKTRQgWHC5gs3YR_3_hD2UVm3M</recordid><startdate>20180120</startdate><enddate>20180120</enddate><creator>Moussa, Ghandoura</creator><creator>Alaaeddine, Rana</creator><creator>Alaeddine, Lynn M.</creator><creator>Nassra, Rasha</creator><creator>Belal, Ahmed S.F.</creator><creator>Ismail, Azza</creator><creator>El-Yazbi, Ahmed F.</creator><creator>Abdel-Ghany, Yasser S.</creator><creator>Hazzaa, Aly</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20180120</creationdate><title>Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study</title><author>Moussa, Ghandoura ; Alaaeddine, Rana ; Alaeddine, Lynn M. ; Nassra, Rasha ; Belal, Ahmed S.F. ; Ismail, Azza ; El-Yazbi, Ahmed F. ; Abdel-Ghany, Yasser S. ; Hazzaa, Aly</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-a0f687933709ac1b8e45aa7c78e33b54e332ee9dbe06cc6fa3e08f34adde5a7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - chemistry</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Arachidonate 15-Lipoxygenase - metabolism</topic><topic>Cell Differentiation - drug effects</topic><topic>Click Chemistry</topic><topic>Click reaction</topic><topic>Cyclooxygenase 1 - metabolism</topic><topic>Cyclooxygenase 1/cyclooxygenase 2</topic><topic>Cyclooxygenase 2 - metabolism</topic><topic>Cyclooxygenase Inhibitors - chemical synthesis</topic><topic>Cyclooxygenase Inhibitors - chemistry</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>Docking</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Design</topic><topic>Drug-likeness</topic><topic>Female</topic><topic>Humans</topic><topic>Lipooxygenase</topic><topic>Lipoxygenase Inhibitors - chemical synthesis</topic><topic>Lipoxygenase Inhibitors - chemistry</topic><topic>Lipoxygenase Inhibitors - pharmacology</topic><topic>Macrophages - drug effects</topic><topic>Molecular Docking Simulation</topic><topic>Molecular Structure</topic><topic>Monocyte/macrophage</topic><topic>Quinazolinones - chemical synthesis</topic><topic>Quinazolinones - chemistry</topic><topic>Quinazolinones - pharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Structure-Activity Relationship</topic><topic>Sulfhydryl Compounds - chemical synthesis</topic><topic>Sulfhydryl Compounds - chemistry</topic><topic>Sulfhydryl Compounds - pharmacology</topic><topic>Thioquinazolinone</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Moussa, Ghandoura</creatorcontrib><creatorcontrib>Alaaeddine, Rana</creatorcontrib><creatorcontrib>Alaeddine, Lynn M.</creatorcontrib><creatorcontrib>Nassra, Rasha</creatorcontrib><creatorcontrib>Belal, Ahmed S.F.</creatorcontrib><creatorcontrib>Ismail, Azza</creatorcontrib><creatorcontrib>El-Yazbi, Ahmed F.</creatorcontrib><creatorcontrib>Abdel-Ghany, Yasser S.</creatorcontrib><creatorcontrib>Hazzaa, Aly</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Moussa, Ghandoura</au><au>Alaaeddine, Rana</au><au>Alaeddine, Lynn M.</au><au>Nassra, Rasha</au><au>Belal, Ahmed S.F.</au><au>Ismail, Azza</au><au>El-Yazbi, Ahmed F.</au><au>Abdel-Ghany, Yasser S.</au><au>Hazzaa, Aly</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2018-01-20</date><risdate>2018</risdate><volume>144</volume><spage>635</spage><epage>650</epage><pages>635-650</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Click chemistry was used to synthesize a new series of thioquinazolinone molecules equipped with propargyl moiety,1,2,3-triazolyl and isoxazolyl rings. Our design was based on merging pharmacophores previously reported to exhibit COX-2 inhibitory activities to a thioquinazolinone-privileged scaffold. The synthesized compounds were subjected to in vitro cyclooxygenase COX-1/COX-2 and 15-LOX inhibition assays. Compounds 2c, 3b, 3h, 3j, and 3k showed COX-2 inhibition with IC50 (μM) 0.18, 0.19, 0.11, 0.16 and 0.17 respectively. These values were compared to celecoxib (IC50 0.05 μM), diclofenac (IC50 0.8 μM) and indomethacin (IC50 0.49 μM) reference drugs. They also showed 15-LOX inhibition with IC50 (μM) 6.21, 4.33, 7.62, 5.21 and 3.98 respectively. These values were compared with Zileuton (IC50 2.41 μM) and Meclofenamate sodium (IC50 5.64 μM) as positive controls. These compounds were further challenged by PMA-induced THP-1 differentiation assay where compounds 2c and 3j inhibited monocyte to macrophage differentiation efficiently with IC50 values of 4.78 μM and 5.63 μM, respectively, compared to that of diclofenac sodium (4.86 μM). On the other hand, 3h demonstrated a significantly increased potency compared to diclofenac in this assay (IC50 = 0.13 μM). The same compounds exhibited significant in vivo anti-inflammatory effect as indicated by the formalin-induced rat-paw edema test. Docking experiments of compounds 2c, 3b, 3h, 3j, and 3k into COX-2 binding pocket have been conducted, where strong binding interactions have been identified and effective overall docking scores have been recorded. Their drug-likeness has been assessed using Molinspiration, Molsoft and Pre-ADMET software products. A new series of propargyl and 1,2,3-Triazolyl thioquinazolinone showed dual COX-2 and LOX inhibitory activity. [Display omitted] •A new series of propargyl, triazolyl and isoxazolyl derivatives of thioquinazolinone were synthesized via click chemistry.•Compounds 2c, 3b, 3h, 3j, and 3k showed dual selective COX-2 and 15-LOX inhibition.•Compounds 2c, 3b, 3h and 3j inhibited in vitro monocyte to macrophage differentiation.•They showed in vivo anti-inflammatory activity and acceptable GIT safety on experimental animals.•Their docking experiments and drug-likeness assessment were satisfactory.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>29289887</pmid><doi>10.1016/j.ejmech.2017.12.065</doi><tpages>16</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2018-01, Vol.144, p.635-650
issn 0223-5234
1768-3254
language eng
recordid cdi_proquest_miscellaneous_1983255799
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
Anti-Inflammatory Agents, Non-Steroidal - chemical synthesis
Anti-Inflammatory Agents, Non-Steroidal - chemistry
Anti-Inflammatory Agents, Non-Steroidal - pharmacology
Arachidonate 15-Lipoxygenase - metabolism
Cell Differentiation - drug effects
Click Chemistry
Click reaction
Cyclooxygenase 1 - metabolism
Cyclooxygenase 1/cyclooxygenase 2
Cyclooxygenase 2 - metabolism
Cyclooxygenase Inhibitors - chemical synthesis
Cyclooxygenase Inhibitors - chemistry
Cyclooxygenase Inhibitors - pharmacology
Docking
Dose-Response Relationship, Drug
Drug Design
Drug-likeness
Female
Humans
Lipooxygenase
Lipoxygenase Inhibitors - chemical synthesis
Lipoxygenase Inhibitors - chemistry
Lipoxygenase Inhibitors - pharmacology
Macrophages - drug effects
Molecular Docking Simulation
Molecular Structure
Monocyte/macrophage
Quinazolinones - chemical synthesis
Quinazolinones - chemistry
Quinazolinones - pharmacology
Rats
Rats, Wistar
Structure-Activity Relationship
Sulfhydryl Compounds - chemical synthesis
Sulfhydryl Compounds - chemistry
Sulfhydryl Compounds - pharmacology
Thioquinazolinone
Tumor Cells, Cultured
title Novel click modifiable thioquinazolinones as anti-inflammatory agents: Design, synthesis, biological evaluation and docking study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T05%3A34%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20click%20modifiable%20thioquinazolinones%20as%20anti-inflammatory%20agents:%20Design,%20synthesis,%20biological%20evaluation%20and%20docking%20study&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Moussa,%20Ghandoura&rft.date=2018-01-20&rft.volume=144&rft.spage=635&rft.epage=650&rft.pages=635-650&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2017.12.065&rft_dat=%3Cproquest_cross%3E1983255799%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1983255799&rft_id=info:pmid/29289887&rft_els_id=S0223523417310966&rfr_iscdi=true